**Author Information** An event is serious (FDA MedWatch definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* requires intervention to prevent permanent impairment or damage

In a case series of studies, 5 children \[*ages at the time of reactions onset not stated*\] were described who developed secondary immunodeficiencies following administration of chemotherapy regimen which consisted of vincristine sulfate \[vincristine\], daunorubicin hydrochloride \[daunorubicin\], cyclophosphamide, pegaspargase, asparaginase, prednisone, methylprednisolone, dexamethasone, cytarabine, methotrexate, hydrocortisone, filgrastim, folinic acid \[leucovorin calcium\], etoposide, mercaptopurine, ciclosporin and mesna \[*time to reactions onsets and outcomes not stated*\].

A child (patient A), who was diagnosed with mixed lineage leukemia gene rearranged acute lymphoblastic leukaemia (MLL-R ALL) at the age of 5 months, started receiving chemotherapy regimen according to study protocol (COG-AALL0631) which consisted of IV vincristine sulfate \[vincristine\], IV daunorubicin hydrochloride \[daunorubicin\], IV cyclophosphamide 1 g/m^2^, IM pegaspargase, asparaginase, oral prednisone, IV methylprednisolone, dexamethasone, cytarabine, methotrexate, intrathecal hydrocortisone, filgrastim, IV folinic acid \[leucovorin calcium\], IV etoposide and oral mercaptopurine \[*not all routes and dosages stated*\]. The child completed chemotherapy at the age of 29 months. The child developed bacterial and fungal infections as treatment course complications. The child also developed secondary immunodeficiencies produced by the chemotherapy which included cytomegalovirus viremia and cystitis, *Clostridium difficile* colitis and *Mycobacterium chelonae* cellulitis. The child\'s immunodeficiencies were confirmed at the age of 31 months. The child died at the age of 31 months due to severe infections. The autopsy results showed disseminated aspergillosis, severe thymic involution and lymphoid depletion.

A child (patient B), who was diagnosed with mixed lineage leukemia gene rearranged acute lymphoblastic leukaemia (MLL-R ALL) at the age of 5 months, started receiving chemotherapy regimen according to study protocol (COG-AALL0631) which consisted of IV vincristine sulfate \[vincristine\], IV daunorubicin hydrochloride \[daunorubicin\], IV cyclophosphamide 1 g/m2, IM pegaspargase, asparaginase, oral prednisone, IV methylprednisolone, dexamethasone, cytarabine, methotrexate, intrathecal hydrocortisone, filgrastim, IV folinic acid \[leucovorin calcium\], IV etoposide and oral mercaptopurine \[*not all routes and dosages stated*\]. The induction amendment was done (elimination of cyclophosphamide 1 g/m2). The child completed chemotherapy at the age of 29 months. The child developed bacterial and viral infections, extensive thrombi involving upper venous system and enteritis as treatment course complications. The child also developed secondary immunodeficiencies produced by the chemotherapy which included *Clostridium difficile* colitis, oral herpes simplex virus infection, norovirus infection, bocavirus infection, rhinovirus infection, and human herpesvirus 6 (HHV-6) viremia, *Enterobacter cloacae* cystitis and pneumatosis intestinalis. The child\'s immunodeficiencies were confirmed at the age of 31 months. The child died at the age of 35 months and the autopsy results showed diffuse bronchopneumonia, severe thymic involution and lymphoid depletion.

A child (patient C), who was diagnosed with mixed lineage leukemia gene rearranged acute lymphoblastic leukaemia (MLL-R ALL) at the age of 7 months, started receiving chemotherapy regimen according to study protocol (COG-AALL0631) which consisted of IV vincristine sulfate \[vincristine\], IV daunorubicin hydrochloride \[daunorubicin\], IV cyclophosphamide 1 g/m2, IM pegaspargase, asparaginase, oral prednisone, IV methylprednisolone, dexamethasone, cytarabine, methotrexate, intrathecal hydrocortisone, filgrastim, IV folinic acid \[leucovorin calcium\], IV etoposide and oral mercaptopurine \[*not all routes and dosages stated*\]. The induction amendment was done (elimination of cyclophosphamide 1 g/m2). The child completed chemotherapy at the age of 31 months. The child did not develop any treatment course complications. The child developed secondary immunodeficiencies produced by the chemotherapy which included *Mycobacterium chelonae* abscesses, parainfluenza-3 infection, coronavirus infection, cytomegalovirus (CMV) retinitis and Candida esophagitis. The child\'s immunodeficiencies were confirmed at the age of 44 months. The child died at the age of 50 months due to severe infections. The autopsy results showed diffuse alveolar damage.

A child (patient D), who was diagnosed with mixed lineage leukemia gene non-rearranged acute lymphoblastic leukaemia (MLL-R ALL) at the age of 8 months, started receiving chemotherapy regimen according to study protocol (CCG-1953) which consisted of vincristine sulfate \[vincristine\], daunorubicin hydrochloride \[daunorubicin\], cyclophosphamide, pegaspargase, asparaginase, prednisone, methylprednisolone, dexamethasone, cytarabine, methotrexate, hydrocortisone, filgrastim, folinic acid \[leucovorin calcium\], etoposide, mercaptopurine, ciclosporin and mesna \[*dosages and routes stated*\]. The child completed chemotherapy at the age of 33 months. The child developed bacterial and viral infections as treatment course complications. The child developed secondary immunodeficiencies produced by the chemotherapy which included pulmonary aspergillosis and pseudomonas sepsis. The child\'s immunodeficiencies were confirmed at the age of 36 months. The child died at the age of 37 months due to severe infections. The autopsy was not performed.

A child (patient E), who was diagnosed with mixed lineage leukemia gene non-rearranged acute lymphoblastic leukaemia (MLL-R ALL) at the age of 11 months, started receiving chemotherapy regimen according to study protocol (COG-P9407[1](#Fn1){ref-type="fn"}) which consisted of filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride \[daunorubicin\], etoposide, folinic acid \[leucovorin calcium\], mercaptopurine, methotrexate, prednisone, hydrocortisone and vincristine sulfate \[vincristine; *not all dosages stated*\]. The child completed the chemotherapy at the age of 24 months. The child developed bacterial infections and chronic rhinorrhea/sinusitis as treatment course complications. The child also developed secondary immunodeficiencies produced by the chemotherapy which included parainfluenza type 3 sinusitis, human herpesvirus 6 (HHV-6) viremia and encephalitis. The child\'s immunodeficiencies were confirmed at the age of 31 months. The child continued to survive.

**Author comment:** \"*Based on the described history and investigations, we concluded these were secondary immunodeficiencies produced by the chemotherapy.*\"

The trial was erroneously mentioned as CCG P9407 in the article.
